0001209191-21-017533.txt : 20210303 0001209191-21-017533.hdr.sgml : 20210303 20210303203609 ACCESSION NUMBER: 0001209191-21-017533 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210301 FILED AS OF DATE: 20210303 DATE AS OF CHANGE: 20210303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ruffo Frank CENTRAL INDEX KEY: 0001654450 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 21712079 MAIL ADDRESS: STREET 1: C/O ACLARIS THERAPEUTICS, INC. STREET 2: 101 LINDENWOOD DRIVE, SUITE 400 CITY: MALVERN STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-01 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001654450 Ruffo Frank C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200 WAYNE PA 19087 0 1 0 0 Chief Financial Officer Common Stock 2021-03-01 4 M 0 25750 A 240939 D Common Stock 2021-03-01 4 F 0 7333 24.06 D 233606 D Common Stock 2021-03-02 4 M 0 8297 A 241903 D Common Stock 2021-03-02 4 F 0 2844 23.25 D 239059 D Employee Stock Option (Right to Buy) 24.06 2021-03-01 4 A 0 116000 0.00 A 2031-02-28 Common Stock 116000 116000 D Restricted stock units 2021-03-01 4 A 0 33200 0.00 A Common Stock 33200 33200 D Restricted stock units 2021-03-01 4 M 0 25750 0.00 D Common Stock 25750 51500 D Restricted stock units 2021-03-02 4 M 0 8297 0.00 D Common Stock 8297 24892 D Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date. The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. /s/ Mark Ballantyne, Attorney-in-fact 2021-03-03